Prognostic Factors in Brain Metastases from Gastrointestinal Cancers: METACER Study

Overview

The METACER national prospective cohort study analyzed 130 patients with brain metastases (BM) from gastrointestinal (GI) cancers, primarily colorectal (CRC) and esogastric cancers (EGC). Key prognostic factors influencing overall survival (OS) included performance status, number of brain lesions, and treatment modalities such as surgery and chemotherapy.

Background

Brain metastases are uncommon at diagnosis in GI cancers but may be underdiagnosed without systematic brain imaging. Prior retrospective studies have shown poor median OS ranging from 2 to 8.7 months after BM diagnosis. Management of BM in GI cancers is not standardized and often extrapolated from other primary tumors like lung or breast cancer. Identifying prognostic factors is critical to guide treatment decisions and improve outcomes in this population.

Data Highlights

Key Findings

• Median overall survival after BM diagnosis remains poor in GI cancers, consistent with literature reports of 2 to 8.7 months.
• Prognostic factors significantly associated with prolonged OS include better WHO performance status, fewer brain metastases, and receipt of surgery or chemotherapy.
• BM incidence in metastatic CRC may be higher than previously reported when systematic brain imaging is performed.
• BM management in GI cancers lacks standardization and relies on multidisciplinary approaches, often extrapolated from other tumor types.
• The METACER study provides prospective data supporting the importance of clinical and treatment-related factors in predicting outcomes.

Clinical Implications

Clinicians should consider performance status and number of brain lesions when assessing prognosis and treatment options for GI cancer patients with BM. Multidisciplinary management including surgery and chemotherapy may improve survival in selected patients. Systematic brain imaging in metastatic GI cancer could aid earlier detection and timely intervention for BM.

Conclusion

The METACER prospective cohort highlights key prognostic factors influencing survival in GI cancer patients with brain metastases, underscoring the need for standardized management strategies and prospective data to optimize outcomes.

References

1. METACER National Cohort Study -- Prospective Analysis of Prognostic Factors in Brain Metastases Among Patients with Gastrointestinal Cancers